Zhonghai Guan

460 total citations
18 papers, 370 citations indexed

About

Zhonghai Guan is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Zhonghai Guan has authored 18 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Neurology and 5 papers in Oncology. Recurrent topics in Zhonghai Guan's work include Neuroblastoma Research and Treatments (4 papers), Renal cell carcinoma treatment (3 papers) and Renal and related cancers (3 papers). Zhonghai Guan is often cited by papers focused on Neuroblastoma Research and Treatments (4 papers), Renal cell carcinoma treatment (3 papers) and Renal and related cancers (3 papers). Zhonghai Guan collaborates with scholars based in China, Singapore and United States. Zhonghai Guan's co-authors include Jiang Cao, Kuifeng He, Haohao Wang, Lisong Teng, Huanrong Lan, Ketao Jin, Jinlin Du, Jinlong Liu, Yuyao Liu and Lisong Teng and has published in prestigious journals such as Journal of Clinical Oncology, Medicine and BioMed Research International.

In The Last Decade

Zhonghai Guan

18 papers receiving 366 citations

Peers

Zhonghai Guan

ONCOL

EPIDE

IMMUN

Chandrika Jeyamohan United States

Ilaria Passacantilli Italy

Shufeng Ji China

Xiaochuang Feng China

Chunbo Zhuang China

Jinxue Tong China

Longci Sun China

Xianghong Yang China

Ana Lameirinhas Portugal

Chandrika Jeyamohan United States

Zhonghai Guan

224 ×0.8

145 ×0.8

89 ×1.1

ONCOL

45 ×1.0

EPIDE

35 ×0.8

IMMUN

Citations per year, relative to Zhonghai Guan Zhonghai Guan (= 1×) peers Chandrika Jeyamohan

Countries citing papers authored by Zhonghai Guan

Since Specialization

Citations

This map shows the geographic impact of Zhonghai Guan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhonghai Guan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhonghai Guan more than expected).

Fields of papers citing papers by Zhonghai Guan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhonghai Guan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhonghai Guan. The network helps show where Zhonghai Guan may publish in the future.

Co-authorship network of co-authors of Zhonghai Guan

This figure shows the co-authorship network connecting the top 25 collaborators of Zhonghai Guan. A scholar is included among the top collaborators of Zhonghai Guan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhonghai Guan. Zhonghai Guan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Wang, Jinhu, Kang Zeng, Xiaoxi Lin, et al.. (2025). Updated data of efficacy and safety of luvometinib (FCN-159) in pediatric participants with neurofibromatosis type 1 from a multi-center, open-label, single-arm phase 2 study.. Journal of Clinical Oncology. 43(16_suppl). 10044–10044. 1 indexed citations

Wang, Jinhu, Kang Zeng, Xiaoxi Lin, et al.. (2024). Efficacy and safety of FCN-159, a MEK1/2 inhibitor in pediatric participants with neurofibromatosis type 1: Results from a phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 3096–3096. 1 indexed citations

Cai, Jiabin, Xuan Wu, Jin‐Yan Wang, et al.. (2023). Perioperative complication incidence and risk factors for retroperitoneal neuroblastoma in children: analysis of 571 patients. World Journal of Pediatrics. 20(3). 250–258. 2 indexed citations

Xiang, Senfeng, Yilong Wang, Zhonghai Guan, et al.. (2023). AKT inhibitor Hu7691 induces differentiation of neuroblastoma cells. Acta Pharmaceutica Sinica B. 13(4). 1522–1536. 5 indexed citations

Guan, Zhonghai, Liang Gong, Weizhong Gu, et al.. (2023). Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR. Pathology. 55(7). 958–965. 1 indexed citations

He, Min, Jiabin Cai, Can Lai, et al.. (2022). Neoadjuvant transcatheter arterial chemoembolization and systemic chemotherapy for the treatment of undifferentiated embryonal sarcoma of the liver in children. World Journal of Clinical Cases. 10(19). 6437–6445. 4 indexed citations

Xu, Fengjiao, Ying Chen, Zhonghai Guan, et al.. (2022). Associated factors on physical activity among childhood cancer survivors in Mainland China: a qualitative exploration applied health belief model. Supportive Care in Cancer. 30(11). 9221–9232. 1 indexed citations

He, Min, Jiabin Cai, Kun Zhu, et al.. (2021). Renal cell carcinoma in children and adolescents. Medicine. 100(2). e23717–e23717. 7 indexed citations

Cai, Jiabin, Jinhu Wang, Min He, et al.. (2021). A novel WT1 gene mutation in a chinese girl with denys‐drash syndrome. Journal of Clinical Laboratory Analysis. 35(5). 1 indexed citations

10.

Lan, Huanrong, Yuyao Liu, Jinlong Liu, et al.. (2021). Tumor-Associated Macrophages Promote Oxaliplatin Resistance via METTL3-Mediated m⁶A of TRAF5 and Necroptosis in Colorectal Cancer. Molecular Pharmaceutics. 18(3). 1026–1037. 81 indexed citations

11.

Cai, Jiabin, et al.. (2020). Paraplegia after transcatheter artery chemoembolization in a child with clear cell sarcoma of the kidney: A case report. World Journal of Clinical Cases. 8(11). 2332–2338. 2 indexed citations

12.

Guan, Zhonghai, Jun Lu, Haohao Wang, et al.. (2018). Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models. Journal of Cancer. 9(7). 1207–1217. 14 indexed citations

13.

Guan, Zhonghai, et al.. (2018). A potential novel therapy for FGFR1‑amplified pancreatic cancer with bone metastasis, screened by next‑generation sequencing and a patient‑derived xenograft model. Oncology Letters. 17(2). 2303–2307. 12 indexed citations

14.

Jiang, Xiaoxia, Xin Xu, Mengjie Wu, et al.. (2018). GPRC5A: An Emerging Biomarker in Human Cancer. BioMed Research International. 2018. 1–11. 30 indexed citations

15.

Guan, Zhonghai, et al.. (2017). Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis. Molecular Medicine Reports. 16(4). 4784–4790. 12 indexed citations

16.

Wang, Haohao, et al.. (2017). LncRNA UCA1 in anti-cancer drug resistance. Oncotarget. 8(38). 64638–64650. 129 indexed citations

17.

Zheng, Lingyan, Cong Xu, Zhonghai Guan, et al.. (2016). Galectin-1 mediates TGF-β-induced transformation from normal fibroblasts into carcinoma-associated fibroblasts and promotes tumor progression in gastric cancer.. PubMed. 8(4). 1641–58. 30 indexed citations

18.

Gu, Yu, Tianxiang Chen, Guangliang Li, et al.. (2016). Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer. Oncotarget. 8(32). 52156–52177. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact